Natural Biocon
7.11
-0.37(-4.95%)
Market Cap₹18.35 Cr
PE Ratio187.00
IndustryChemicals
Company Performance:
1D-4.95%
1M-28.83%
6M-44.28%
1Y-43.30%
5Y-54.45%
View Company Insightsright
Latest news about Natural Biocon
Biocon Secures Approval for Generic Liraglutide in India, Expanding Diabetes Treatment Options Jun 03, 2025
Biocon has obtained regulatory approval for its generic version of Victoza (Liraglutide) to treat Type 2 diabetes in India. This approval expands Biocon's diabetes care portfolio and could potentially increase access to affordable diabetes treatment for millions of Indians. The introduction of generic Liraglutide is expected to increase competition in the diabetes care market, potentially leading to lower treatment costs and more options for patients. Launch date and pricing details are yet to be announced.
Biocon Biologics Advances in European Market with Positive CHMP Opinions for Biosimilar Denosumab Apr 28, 2025
Biocon Unveils Ambitious 45 Billion Rupee Fundraising Plan Amid Financial Growth Apr 24, 2025